DE69839423D1 - Verfahren zur prevention von gastritis unter verwendung von amylin oder amylin agonisten - Google Patents

Verfahren zur prevention von gastritis unter verwendung von amylin oder amylin agonisten

Info

Publication number
DE69839423D1
DE69839423D1 DE69839423T DE69839423T DE69839423D1 DE 69839423 D1 DE69839423 D1 DE 69839423D1 DE 69839423 T DE69839423 T DE 69839423T DE 69839423 T DE69839423 T DE 69839423T DE 69839423 D1 DE69839423 D1 DE 69839423D1
Authority
DE
Germany
Prior art keywords
amylin
gastritis
agonist
prevention
agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69839423T
Other languages
English (en)
Other versions
DE69839423T2 (de
Inventor
Andrew Young
Bronislava Gedulin
Gareth Wyn Beynon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Application granted granted Critical
Publication of DE69839423D1 publication Critical patent/DE69839423D1/de
Publication of DE69839423T2 publication Critical patent/DE69839423T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69839423T 1997-05-06 1998-05-06 Verfahren zur prevention von gastritis unter verwendung von amylin oder amylin agonisten Expired - Lifetime DE69839423T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US851965 1997-05-06
US08/851,965 US7101853B2 (en) 1997-05-06 1997-05-06 Method for treating or preventing gastritis using amylin or amylin agonists
PCT/US1998/009089 WO1998050059A1 (en) 1997-05-06 1998-05-06 Method for preventing gastritis using amylin or amylin agonists

Publications (2)

Publication Number Publication Date
DE69839423D1 true DE69839423D1 (de) 2008-06-12
DE69839423T2 DE69839423T2 (de) 2009-06-04

Family

ID=25312164

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69839423T Expired - Lifetime DE69839423T2 (de) 1997-05-06 1998-05-06 Verfahren zur prevention von gastritis unter verwendung von amylin oder amylin agonisten

Country Status (9)

Country Link
US (1) US7101853B2 (de)
EP (2) EP1952819A3 (de)
JP (1) JP2001526656A (de)
AT (1) ATE393630T1 (de)
AU (1) AU7284098A (de)
CA (1) CA2289548A1 (de)
DE (1) DE69839423T2 (de)
ES (1) ES2302353T3 (de)
WO (1) WO1998050059A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2319936T5 (es) 1996-08-08 2013-06-24 Amylin Pharmaceuticals, Inc. Regulación de la motilidad gastrointestinal
US8114958B2 (en) 2004-02-11 2012-02-14 Amylin Pharmaceuticals, Inc. Amylin family peptides
US7399744B2 (en) 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
AU2006223161B2 (en) * 2005-03-11 2011-05-12 Endo Pharmaceuticals Solutions Inc. Controlled release formulations of octreotide
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
AU2006230420B2 (en) * 2005-03-31 2011-11-24 Amylin Pharmaceuticals, Llc Compositions and methods for the control, prevention, and treatment of obesity and eating disorders
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US11225404B2 (en) 2006-12-13 2022-01-18 Crown Equipment Corporation Information system for industrial vehicles
JP5536053B2 (ja) * 2008-06-25 2014-07-02 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド． 離型剤を有するオクトレオチドインプラント
US8071537B2 (en) 2008-06-25 2011-12-06 Endo Pharmaceuticals Solutions Inc. Implantable device for the sustained release of a polypeptide
BR102013017626A2 (pt) * 2013-06-14 2015-02-10 Univ Rio De Janeiro Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
JP2015066978A (ja) * 2013-09-26 2015-04-13 ヤマハ発動機株式会社 船舶用表示システムおよびそれを備えた小型船舶
MX2017011182A (es) 2015-03-18 2018-06-06 Zealand Pharma As Analogos de amilina.
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
US11274158B2 (en) * 2018-01-30 2022-03-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators
CA3097812A1 (en) * 2018-04-25 2019-10-31 Janssen Pharmaceutica Nv Thioether cyclic peptide amylin receptor modulators
US20230082544A1 (en) 2020-02-18 2023-03-16 Novo Nordisk A/S Pharmaceutical formulations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3514097A (en) 1967-11-13 1970-05-26 Gen Binding Corp Canada Ltd Folding apparatus for paper and the like
US4528193A (en) * 1978-12-27 1985-07-09 A. Natterman & Cie. Gmbh Inflammation-preventing pharmaceutical composition of oral administration
US4530838A (en) * 1983-07-08 1985-07-23 The Salk Institute For Biological Studies Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals
US5367052A (en) 1987-04-27 1994-11-22 Amylin Pharmaceuticals, Inc. Amylin peptides
GB8720115D0 (en) 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US5175145A (en) 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
US5264372A (en) 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
DK0567626T3 (da) * 1991-11-19 2001-12-17 Amylin Pharmaceuticals Inc Amylin-agonist-peptider og anvendelse deraf
US5376638A (en) 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
CN1095284A (zh) * 1993-05-15 1994-11-23 浙江永宁制药厂 治疗胃与十二指肠溃疡的药物配方和加工方法
RU2177331C2 (ru) 1993-09-07 2001-12-27 Амилин Фармасьютикалз, Инк. Способы регулирования моторики желудочно-кишечного тракта
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
CN1055219C (zh) * 1995-07-21 2000-08-09 哈尔滨世一堂制药厂 一种治疗胃病的药物及其制法
US5677279A (en) * 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US11838193B1 (en) 2022-12-16 2023-12-05 Amazon Technologies, Inc. Real-time load limit measurement for a plurality of nodes

Also Published As

Publication number Publication date
US7101853B2 (en) 2006-09-05
CA2289548A1 (en) 1998-11-12
EP0981360B1 (de) 2008-04-30
EP1952819A2 (de) 2008-08-06
EP0981360A4 (de) 2001-05-23
US20020010133A1 (en) 2002-01-24
EP0981360A1 (de) 2000-03-01
DE69839423T2 (de) 2009-06-04
JP2001526656A (ja) 2001-12-18
AU7284098A (en) 1998-11-27
ATE393630T1 (de) 2008-05-15
ES2302353T3 (es) 2008-07-01
WO1998050059A1 (en) 1998-11-12
EP1952819A3 (de) 2008-10-22

Similar Documents

Publication Publication Date Title
DE69839423D1 (de) Verfahren zur prevention von gastritis unter verwendung von amylin oder amylin agonisten
YU39695A (sh) Formulacija analoga insulina
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
MX163955B (es) Composicion farmaceutica de dihidrocodeina e ibuprofen
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
ATE322905T1 (de) Verfahren zur hemmung der fibrose mittels eines somatostatin-agonisten
DE69533112T2 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
ATE96678T1 (de) Verfahren zur verminderung von hautirritationen bei anwendung von durchdringungsverstaerkenden arzneimittelzusammensetzungen.
NO920051L (no) Farmasoeytisk sammensetning for slanking
PT772451E (pt) Tratamento da diabetes mellitus tipo ii com antagonistas de amilina
BR9910180A (pt) Composição farmacêutica, processos para o tratamento de uma condição associada com a transmissão reduzida de nicotina, para identificação de um modulador positivo de um agonista receptor nicotìnico e para identificação de um composto, composto, e, uso de um modulador positivo de um agonista receptor nicotìnico
DE58901401D1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
DE3650358D1 (de) Diphosphonate enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Arthrosis.
DE69615984D1 (de) Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen
BR9915390A (pt) Tratamento de tumores através de administração de compostos que liberam harmÈnio de crescimento e seus antagonistas
FR2585572B3 (fr) Nouvelles compositions pharmaceutiques a base d'un sel de l'acide p. chlorophenoxyacetique destinees au traitement des neuropathies et assurant la regeneration nerveuse
ATE200617T1 (de) Pharmazeutische zusammensetzungen zur transdermalen verabreichung von melatonin und/oder seine analoge
PT980253E (pt) Somatostatina e agonistas de somatostatina para tratar a insensibilidade a insulina e a sindrome x
IL126175A (en) Pharmaceutical compositions containing endothelin antagonists and novel endothelin antagonists
ATE245998T1 (de) Somatostatin agoniste zur reduzierung von körpergewicht
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
AR007059A1 (es) Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto
SE8800461D0 (sv) Farmaceutisk komposition
ATE78160T1 (de) Verwendung von ''naftidrofuryl'' zur behandlung von neuropathien.
ATE318612T1 (de) Methoden und zusammensetzungen zur behandlung der hyperlipidämie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition